Clinical Trials Directory

Trials / Completed

CompletedNCT05181046

Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients

Non-inferiority of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Patients With Open-angle Glaucoma or Ocular Hypertension

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
420 (actual)
Sponsor
Nanodropper, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effect of microdrops vs. standard eyedrops of 0.5% timolol maleate in adults with primary open-angle glaucoma or ocular hypertension in terms of intraocular pressure-lowering efficacy and cardiovascular side effects.

Detailed description

This randomized, single-masked, parallel study aims to evaluate the safety and efficacy of microdrops of 0.5% timolol maleate administered with Nanodropper (experimental intervention) compared to standard drops of 0.5% timolol maleate (active comparator) in patients with primary open-angle glaucoma (OAG) or ocular hypertension (OHT) at Aravind Eye Hospital. At the beginning of the test day, baseline (pre-drug) intraocular pressure (IOP), resting heart rate (HR), and resting systolic and diastolic blood pressure (BP) measurements will be collected. Participants will be randomized to receive standard eyedrops or microdrops of 0.5% timolol maleate (one drop per eye), which will be administered by a trained technician at t = 0. IOP, HR, and BP measurements will be repeated by a masked investigator at t = 1, 2, 5, and 8 hours after drug administration.

Conditions

Interventions

TypeNameDescription
DEVICENanodropper adaptorThe Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
OTHEROriginal eyedrop bottle/No NanodropperThe original eyedrop bottle dispenses standard eyedrops.

Timeline

Start date
2021-11-06
Primary completion
2022-12-19
Completion
2022-12-19
First posted
2022-01-06
Last updated
2023-01-18

Locations

2 sites across 1 country: India

Regulatory

Source: ClinicalTrials.gov record NCT05181046. Inclusion in this directory is not an endorsement.